Return to content in this issue

 

First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

Pérez de Llano LA1*, Cosío BG2,3,4*, Lobato Astiárraga I5, Soto Campos G6, Tejedor Alonso MA7, Marina Malanda N8, Padilla Galo A9, Urrutia Landa I10, Michel de la Rosa FJ11, García-Moguel I12, on behalf of the Reslizumab Real-Life Spanish group**

1Pulmonology Department, Hospital Lucus Augusti, Lugo, Spain
2Pulmonology Department, Hospital Universitario Son Espases, Illes Balears, Spain
3Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Palma de Mallorca, Spain
4CIBER de enfermedades respiratorias (CIBERES), Madrid, Spain
5Pulmonology Department, Complejo Asistencial de Ávila, Ávila, Spain
6Pulmonology and Allergy Unit, University Hospital of Jerez, Jerez de la Frontera, Cádiz, Spain
7Allergy Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain
8Pulmonology Department, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
9Pulmonology Department, Hospital Costa del Sol, Marbella, Málaga, Spain
10Respiratory Medicine Department, Galdakao Hospital, Galdakao, Bizkaia, Spain
11Pulmonology Department, Hospital Universitario Donostia, San Sebastián, Spain
12Department of Allergy, Hospital Universitario 12 de Octubre, Madrid, Spain
*Co-primary authors
**The full list of the Reslizumab real-life Spanish group is included in the appendix.

J Investig Allergol Clin Immunol 2023; Vol 33(3) : 220-222
doi: 10.18176/jiaci.0839

Key words: Eosinophilic asthma, Reslizumab, Asthma control, Monoclonal antibodies